Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06188208 · ClinicalTrials.gov registry record · Phase 1

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors

A Phase 1 study of Advanced Solid Tumors and Advanced Hematologic Tumors, sponsored by Vividion Therapeutics.

Active
Registry status
Phase 1
Development phase
125
Enrollment target
20
Study locations

NCT06188208 is a Phase 1 study of Advanced Solid Tumors and Advanced Hematologic Tumors that is active but no longer recruiting, run by Vividion Therapeutics. The registered enrollment target is 125 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (37% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06188208, a Phase 1 study of Advanced Solid Tumors and Advanced Hematologic Tumors, is active but no longer recruiting, sponsored by Vividion Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
125 participants
Enrollment target
20
Study locations

Study Summary

A FIH study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VVD-130850, as single agent and in combination with checkpoint inhibition, in participants with advanced solid and hematologic tumors.

Conditions Studied

Advanced Solid Tumors Advanced Hematologic Tumors

Interventions

  • DRUG Pembrolizumab
  • DRUG VVD-130850

Study Locations (20)

Other

  • Cancer Research South Australia - Adelaide
  • ICON Cancer Research - South Brisbane
  • START Barcelona Hospital HM Nou Delfos - Barcelona
  • Vall d'Hebron - Barcelona
  • Hospital Universitario 12 de Octubre - Madrid
  • NEXT Madrid - Madrid
  • START Madrid CIOCC - Madrid
  • Start Madrid-FJD, Hospital Fundacion Jimenez Diaz - Madrid

Texas

  • NEXT Austin - Austin
  • MDACC - Houston
  • NEXT Dallas - Irving
  • NEXT San Antonio - San Antonio

New South Wales

  • Blacktown Hospital - Blacktown
  • Orange Health Service - Orange

California

  • California Research Institute - Los Angeles

Florida

  • Florida Cancer Specialists - Sarasota

Tennessee

  • Sarah Cannon Research Institute - Nashville

Utah

  • University of Utah Huntsman Cancer Institute - Salt Lake City

Virginia

  • NEXT Virginia - Fairfax

Trial Details

FieldValue
Enrollment Target 125 participants
Start Date 2024-01-05
Est. Completion 2027-01
Phase Phase 1

Sponsor

Vividion Therapeutics

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06188208

The ClinicalTrials.gov registry entry for NCT06188208 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (37% lower). The listed sponsor is Vividion Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT06188208 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Texas, New South Wales.

Frequently Asked Questions

What is clinical trial NCT06188208 about?

NCT06188208 is a clinical study titled "A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors". A FIH study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VVD-130850, as single agent and in combination with checkpoint inhibition, in participants with advanced solid and hematologic tumors.

What is the current status of trial NCT06188208?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 125 participants. The study started on 2024-01-05. Estimated completion is 2027-01.

What conditions does trial NCT06188208 study?

This clinical trial studies the following conditions: Advanced Solid Tumors, Advanced Hematologic Tumors.

What interventions are being tested in trial NCT06188208?

The interventions under investigation include: Pembrolizumab (DRUG), VVD-130850 (DRUG).

Who is sponsoring clinical trial NCT06188208?

This trial is sponsored by Vividion Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06188208 being conducted?

This trial has 20 study locations across California, Florida, Tennessee, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

Advanced Hematologic Tumors

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.